Cerevel Therapeutics Holdings EPS Ratio 2011-2026 | CERE

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Cerevel Therapeutics Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.67	-2.32	-1.65	-2.01	-2.9	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-1.65	-2.9	-2.31

Quarterly EPS Ratio Cerevel Therapeutics Holdings

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.73	-	-0.61	-0.63	-0.67	-	-0.66	-0.61	-0.46	-	-0.43	-0.42	-0.4	-	-0.62	-0.44	-0.87	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.4	-0.87	-0.581

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	2.1	$ 21.65	-	$ 1.01 B	USA
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Allakos ALLK	-2.14	-	-	$ 28.6 M	USA
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-1.42	-	-	$ 8.42 M	USA
Aptorum Group Limited APM	-0.19	$ 0.9	-0.18 %	$ 6.62 M	China
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.37	$ 22.3	-	$ 3.7 B	USA
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Brainstorm Cell Therapeutics BCLI	-1.11	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Cara Therapeutics CARA	-2.46	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	-0.27	-	-	$ 35.4 M	USA
Fennec Pharmaceuticals FENC	-0.34	$ 6.85	-	$ 196 M	USA
ChromaDex Corporation CDXC	0.22	-	-0.88 %	$ 598 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Galectin Therapeutics GALT	-0.48	$ 2.37	-	$ 151 M	USA
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
Greenwich LifeSciences GLSI	-1.21	$ 23.99	-	$ 312 M	USA
Aridis Pharmaceuticals ARDS	-1.62	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	42.2	$ 102.06	-	$ 27.2 B	Germany
Checkpoint Therapeutics CKPT	-1.42	-	-	$ 169 M	USA
Avenue Therapeutics ATXI	-0.93	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Heron Therapeutics HRTX	-0.12	$ 1.19	-	$ 198 M	USA
Aquestive Therapeutics AQST	-0.78	$ 4.1	-	$ 438 M	USA
Arcutis Biotherapeutics ARQT	-0.13	$ 23.42	-	$ 2.98 B	USA
ImmuCell Corporation ICCC	-0.12	$ 8.25	-	$ 74.5 M	USA
Autolus Therapeutics plc AUTL	-1.08	$ 1.42	-	$ 378 M	Britain
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
AstraZeneca PLC AZN	0.08	-	-	$ 96.9 B	Britain
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Inventiva S.A. IVA	-1.27	$ 5.13	-	$ 138 M	France
Can-Fite BioPharma Ltd. CANF	-5.97	$ 2.92	-	$ 4.81 M	Israel
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
Kamada Ltd. KMDA	-0.05	$ 8.2	-	$ 260 M	Israel